Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 36Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Adenocarcinoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Melanoma 3Breast Neoplasms, Male 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Metastatic Pancreatic Adenocarcinoma 2Carcinoma 2Advanced Solid Tumor 2Tongue Neoplasms 1Thymus Neoplasms 1Solid Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Ovarian Neoplasms 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Albumin-Bound Paclitaxel × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡